Please use this identifier to cite or link to this item: http://sgc.anlis.gob.ar/handle/123456789/2117
DC FieldValueLanguage
dc.contributor.authorAmbrosio, Ana Maríaes
dc.contributor.authorMariani, Mauricioes
dc.contributor.authorMaiza, Andreaes
dc.contributor.authorGamboa, Gracielaes
dc.contributor.authorFossa, Sebastiánes
dc.contributor.authorBottale, Alejandro Javieres
dc.date.accessioned2021-01-13T00:44:39Z-
dc.date.available2021-01-13T00:44:39Z-
dc.date.issued2018-
dc.identifier.issn1064-3745-
dc.identifier.urihttp://sgc.anlis.gob.ar/handle/123456789/2117-
dc.descriptionFil: Ambrosio, Ana María. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.es
dc.descriptionFil: Mariani, Mauricio. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.es
dc.descriptionFil: Maiza, Andrea. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.es
dc.descriptionFil: Gamboa, Graciela. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.es
dc.descriptionFil: Fossa, Sebastián Edgardo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.es
dc.descriptionFil: Bottale, Alejando Javier. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.es
dc.description.abstractArgentinian hemorrhagic Fever (AHF) is a febrile, acute disease caused by Junín virus (JUNV), a member of the Arenaviridae. Different approaches to obtain an effective antigen to prevent AHF using complete live or inactivated virus, as well as molecular constructs, have reached diverse development stages. This chapter refers to JUNV live attenuated vaccine strain Candid #1, currently used in Argentina to prevent AHF. A general standardized protocol used at Instituto Nacional de Enfermedades Virales Humanas (Pergamino, Pcia. Buenos Aires, Argentina) to manufacture the tissue culture derived Candid #1 vaccine is described. Intermediate stages like viral seeds and cell culture bank management, bulk vaccine manufacture, and finished product processing are also separately presented in terms of Production and Quality Control/Quality Assurance requirements, under the Adminitracion Nacional de Medicamentos, Alimentos y Tecnología Medica (ANMAT), the Argentine national regulatory authority.es
dc.language.isoenes
dc.publisherHumana Presses
dc.relation.ispartofMethods in molecular biology (Clifton, N.J.)es
dc.rightsClosed Access-
dc.sourceMethods in Molecular Biology 2018;1604:305-329.-
dc.subjectFiebre Hemorrágica Americanaes
dc.subjectArenaviridaees
dc.subjectVirus Junines
dc.titleProtocol for the Production of a Vaccine Against Argentinian Hemorrhagic Feveres
dc.typeArtículoes
dc.identifier.doi10.1007/978-1-4939-6981-4_24-
anlis.essnrd1-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairetypeArtículo-
item.fulltextNo Fulltext-
item.languageiso639-1en-
crisitem.author.deptAdministración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos G. Malbrán” (ANLIS)-
crisitem.author.deptInstituto Nacional de Enfermedades Virales Humanas (INEVH)-
crisitem.author.parentorgAdministración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos G. Malbrán” (ANLIS)-
Appears in Collections:Publicaciones INEVH
Show simple item record

Page view(s)

14
checked on May 2, 2024

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.